ReviewSubstance abuse and rehabilitation2014
Nalmefene: a new approach to the treatment of alcohol dependence.
Review in Substance abuse and rehabilitation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Cannabidiol as a Novel Candidate Alcohol Use Disorder Pharmacotherapy: A Systematic Review.Alcoholism, clinical and experimental research · 2019Pooled it
- Pooled it
- MDMA-assisted psychotherapy for AUD: Bayesian analysis of WHO drinking risk level and exploratory analysis of drinking behavior and psychosocial functioning at 3 months follow-up.Alcohol and alcoholism (Oxford, Oxfordshire) · 2025Article
- Nalmefene enhances the remyelinating ability of nalfurafine when administered therapeutically at very low doses during experimental autoimmune encephalomyelitis.Clinical & translational immunology · 2025Article
- GABAergic signaling in alcohol use disorder and withdrawal: pathological involvement and therapeutic potential.Frontiers in neural circuits · 2023Review
- Regulation of alcohol drinking by ventral striatum and extended amygdala circuitry.Neuropharmacology · 2022Review
- Alcohol-Related Liver Disease: Basic Mechanisms and Clinical Perspectives.International journal of molecular sciences · 2021Review
- A case report of Multiple Symmetric Lipomatosis (MSL) in an East Asian Female.BMC women's health · 2020Article
- Prevention, screening, and treatment for heavy drinking and alcohol use disorder.The lancet. Psychiatry · 2019Review
- Access to care for people with alcohol use disorder in France: a mixed-method cross-sectional study protocol (ASIA).BMJ open · 2018Article
- Medications development for the treatment of alcohol use disorder: insights into the predictive value of animal and human laboratory models.Addiction biology · 2017Review
- Exploration of Core Symptoms for the Diagnosis of Alcohol Dependence in the ICD-10.Alcoholism, clinical and experimental research · 2016Article
- A Point-by-Point Response to Braillon.CNS neuroscience & therapeutics · 2016Article
- Drugs to Treat Alcohol Dependence-A Perspective.Journal of addiction and dependence · 2016Article
- Disclosure of conflicts of interest and credibility for the medical profession.Substance abuse and rehabilitation · 2016Article
- Harm Reduction as "Continuum Care" in Alcohol Abuse Disorder.International journal of environmental research and public health · 2015Article
- Severe opioid withdrawal syndrome after a single dose of nalmefene.European journal of clinical pharmacology · 2015Article
- Nalmefene and alcohol dependence: A new approach or the same old unacceptable marketing?Substance abuse and rehabilitation · 2015Article
Corrections and comments
- Erratum issued
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reduction of alcohol consumption is not yet a widely accepted treatment objective for alcohol-dependent patients, as abstinence is often considered to be the only possible objective in this situation. However, various studies have demonstrated the value of proposing these two options to such patients. Firstly, reduction of alcohol consumption very significantly reduces the risk of alcohol-related damage, and also modifies the patient's and the doctor's perception of the disease, resulting in improved access to care and better patient adherence with the proposed treatment objective and consequently better clinical results. Recent studies have shown that some medicinal products can help patients reduce their alcohol consumption. One such product, nalmefene, has been granted European marketing authorization and is now being released onto the market in various countries. The ESENSE 1 and 2 studies in alcohol-dependent patients showed that, in combination with BRENDA, a psychosocial intervention focusing on reinforcement of motivation and treatment adherence, nalmefene significantly reduced the number of heavy drinking days and mean daily total alcohol consumption versus placebo. This reduction was more marked in the marketing authorization target population, ie, patients with a high or very high drinking risk level according to World Health Organization criteria. Another original feature of this molecule is that it can be used as needed if the patient perceives a risk of drinking, which is a more flexible approach and more likely to ensure the patient's active involvement in the treatment of his/her disease. This molecule opens up interesting and original therapeutic prospects in the treatment of alcohol dependence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.